Wirth Andrew, Seymour John F, Hicks Rodney J, Ware Robert, Fisher Richard, Prince Miles, MacManus Michael P, Ryan Gail, Januszewicz Henry, Wolf Max
Division of Radiation Oncology, Peter McCallum Cancer Institute, East Melbourne, Victoria, Australia.
Am J Med. 2002 Mar;112(4):262-8. doi: 10.1016/s0002-9343(01)01117-2.
To compare fluorine-18 fluorodeoxyglucose positron emission tomography (PET) and gallium scanning with each other and with conventional staging, for patients with Hodgkin's disease or non-Hodgkin's lymphoma.
Fifty patients had PET, gallium scanning, and conventional staging of newly diagnosed or progressive Hodgkin's disease or non-Hodgkin's lymphoma. Disease sites, stage, and treatment plans were assessed retrospectively.
Positron emission tomography and gallium scanning each upstaged 14% of patients (n = 7). Management was altered by PET in 9 cases (18%) and by gallium scanning in 7 (14%, P = 0.6). Disease was evident in 117 sites in 42 patients. The case positivity rate for conventional assessment was 90%; for PET, 95%; for gallium scanning, 88%; for conventional assessment plus PET, 100%; and for conventional assessment plus gallium scanning, 98%. Site positivity rates for conventional assessment were 68%; for PET, 82%; for gallium scanning, 69% (conventional vs. PET, P = 0.01; conventional vs. gallium scanning, P = 0.9; PET vs. gallium scanning, P = 0.01); for conventional assessment plus PET, 96%; and for conventional assessment plus gallium scanning, 94%. Positron emission tomography and gallium scanning were entirely concordant in 31 patients; in the other 19 patients, PET identified 25 sites missed by gallium scanning, whereas gallium scanning identified 10 sites missed by PET.
In this retrospective study, PET demonstrated a higher site positivity rate than did gallium scanning, with similar case positivity rates. These data support the use of PET in place of gallium scanning for the staging of patients with Hodgkin's disease or non-Hodgkin's lymphoma.
比较氟-18氟脱氧葡萄糖正电子发射断层扫描（PET）和镓扫描在霍奇金病或非霍奇金淋巴瘤患者中的应用，并与传统分期方法进行对比。
50例新诊断或病情进展的霍奇金病或非霍奇金淋巴瘤患者接受了PET、镓扫描及传统分期检查。对疾病部位、分期及治疗方案进行回顾性评估。
PET和镓扫描均使14%（n = 7）的患者分期上调。PET改变了9例（18%）患者的治疗管理，镓扫描改变了7例（14%）患者的治疗管理（P = 0.6）。42例患者的117个部位发现了病变。传统评估的病例阳性率为90%；PET为95%；镓扫描为88%；传统评估加PET为100%；传统评估加镓扫描为98%。传统评估的部位阳性率为68%；PET为82%；镓扫描为69%（传统评估与PET对比，P = 0.01；传统评估与镓扫描对比，P = 0.9；PET与镓扫描对比，P = 0.01）；传统评估加PET为96%；传统评估加镓扫描为94%。PET和镓扫描在31例患者中结果完全一致；在另外19例患者中，PET发现了25个镓扫描遗漏的部位，而镓扫描发现了10个PET遗漏的部位。
在这项回顾性研究中，PET显示出比镓扫描更高的部位阳性率，病例阳性率相似。这些数据支持在霍奇金病或非霍奇金淋巴瘤患者分期中使用PET替代镓扫描。
